Regeneron's linvoseltamab gets positive EU regulatory opinion
Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
EMA支持Regeneron公司的linvoseltamab用于多发性骨髓瘤治疗
纽约塔里敦 - 市值达752亿美元、年收入142亿美元的生物科技公司Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)获得欧洲药品管理局 (EMA)人用药品委员会 (CHMP)对其候选药物linvoseltamab的积极意见。该药物用于治疗复发和难治性多发性骨髓瘤 (R/R MM)成年患者。根据 InvestingPro ...
Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab
Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...
Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple ...
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Investing3 天
EMA backs Regeneron’s linvoseltamab for multiple myeloma
Linvoseltamab, which is still under investigation ... For investors tracking Regeneron’s potential in this market, InvestingPro data shows the company’s strong market position is supported ...